Parexel, Kendle, Quintiles, Encorium Group, Icon and Aesica - People on the move
have all had people on the move in the world of
pharmaceutical outsourcing.
Parexel has appointed biostatistician Dr Imogene Grimes to the post of vice president of Data Sciences, Strategic Services.
The contract research organisation (CRO) said that Grimes will be contributing to the continued expansion of its data science services, where her responsibilities include advising clients on clinical study design, analysis methodology, and related regulatory guidelines, as well as providing support for strategic data services, such as preparation of integrated data files suitable for registration packages and preparation of electronic submissions, compliant with regulatory expectations.
Prior to joining Parexel, she served as vice president of Statistics, Data Management and Informatics at Regeneron Pharmaceuticals.
Recently, Kendle has promoted S imon Higginbotham to the role of president, taking over the role from Chris Bergen , who will remain on in the position of chief operating officer.
In his new role as president, Higginbotham will provide global leadership for worldwide customer and business expansion to include strategic customer relations and new market opportunities, the firm said.
At the same time, assuming the position of vice president and chief marketing officer held previously by Higginbotham is Alan Boyce.
Until now he has served with the company as vice president of global clinical development for Europe and Africa.
Meanwhile, at the world's top CRO Quintiles, Oren Cohen , company chief medical and scientific officer, has been handed additional responsibilities.
Cohen has now taken on the role of senior vice president for clinical research strategies, while continuing to serve in his currentl capacity of managing director of Quintiles Public Health and Government Services.
In his new post, Cohen will will be responsible for evaluating and implementing the company's new clinical research strategies.
Over at Encorium Group , the resignation of Lawrence Hoffman , the company's chief financial officer, has been revealed.
" Effective May 2, 2008, Mr Hoffman has decided to leave the company to pursue other interests ," said a statement from Encorium.
Hoffman has served with the CRO for the past four years.
" We have retained the services of an executive search firm to spearhead this recruitment effort, and will appoint an interim chief financial officer in the near future ," Kai Lindevall, Encorium's CEO and Kenneth Borow, Encorium's president and chief medical and strategic development officer jointly commented.
Meanwhile, Icon has announced the appointments of Dr Tom McCloskey as associate director of Cellular Immunology, Research and Development and Dr Alamelu Chandrasekaran to the position of manager, Molecular Diagnostics at Icon Central Laboratories.
Prior to joining Icon, McCloskey served as director of Flow Cytometry for the Department of Pediatrics at North Shore University Hospital, and most recently as scientist-in-charge for the Flow Cytometry Core Facility.
Chandrasekaran has been working as a research associate and research scientist at North Shore-LIJ Research Core facility and Genomics Center, where she managed QPCR and Microarray facilities.
Finally, active pharmaceutical ingredients (API) and formulated products supplier Aesica has announced the appointment of Anthony Higham as operations Director.
He joins the company from GlaxoSmithKline where he was a divisional technical head within its Global Manufacturing and Supply division.
At Aesica, Higham will be responsible for operations across the company's three UK manufacturing sites in Northumberland, Enfield and Queenborough.
The sites provide primary and secondary manufacturing capabilities and supply many of the world's top ten pharmaceutical companies, emerging life science companies and generic manufacturers.
